. >>> regeneron's life-saving covid cocktail. >>> an implosion clears the way for clear energy. >>> and the millennial lifestyle, getting pricey. >> announcer: live from cnbc, the facts, the truth, "the news with shepard smith." >>> good evening after months of rising tensions, president biden finally met face-to-face with vladimir putin. mr. biden says the summit in geneva was not a kumbaya moment, but an opportunity to confront putin on russian cyber attacks t human rights abuses and other issues that have driven the u.s./russia relationship to one of the lowest points since the cold war >> the bottom line is i told president putin we need some basic rules of the road that we can all abide by it was important to meet in person, so there can be no mistake or misrepresentations about what i wanted to communicate. >> i did what i came to do s>> president biden says he lai down the red lines and warned president putin that the consequences would be devastating for russia if alexei navalny dies in prison reporters pressed mr. putin on his treatment of navalny and other opponents who have a

regeneron's covid data dr. scott gottlieb is here to weigh in it's june 16th, 2021 and "squawk box" begins right now. >>> good morning, everybody. welcome to "squawk box" here on cnbc i'm becky quick along with andrew ross sorkin and mike santoli. joe is off, mike, great to have you with us. >> great to be here. >> yeah, we were just talking about how beautiful times square is and what a magnificent place this is. you see they got rid of the port-a-potties so we got that going for us today >>> let's take a look at the market dow is down by 55 points, s&p down by 2, nasdaq up by close to 10 days. the nasdaq was the biggest decliner down, down by 7 0.7% people waiting to see what the odds are mike, what do you think with the snap of activity >> i think there's always a snap of activity. the market is being held in place just to see if expectations are confirmed that there's more of an acknowledgement that they're getting closer to this point where they have to withdraw the bond-buying down the road. they have to

a new trial shows regeneron can cut death by 20%.udy includes 10,000 hospitalized patients who did not have antibody response on their own. currently treatment on out-patients. emergency use authorization for those hospitalized with the virus. regeneron shares are up half a percent in the premarket. well, finally face to face, russian president vladimir putin are set to meet in geneva switzerland, first time they have met since taking office and president biden called on putin and his government for cyber-attacks. he called them out for cyber attacks on u.s. interest, election interference and russian's handling of political opponents. joining right now washington times, opinion editor charles hurt and also joining the conversation all morning long fox business dagen mcdowell and former media chairman and former republican presidential candidate himself steve forbes. former chairman of forbes media. all right, great to see everybody this morning. thank you so much for being here. charles, kicking things off with you, what are you exp

and antibody cocktail made by regeneron is showing promise. to a study, the therapy reduced the risk of death among hospitalized covid patients by 20%. patients also spent four days less in the hospital on average. regeneron says the benefit is only for people whose bodies don't naturally produce antibody's. google won a deal to provide v mh with five based artificial intelligence solutions. the aim, the personalize experiences for customers and faster long-term growth. google will also work with their individual brand to help them recommend targets -- recommend products to targeted clients. tomorrow, dafydd boston will speak with brian moynihan. you don't want to miss that. cap studio 1.0 tonight. this is bloomberg. ♪ >> good morning, welcome to "daybreak: australia." >> we are counting down to asia's major market opens. >> good evening. top stories this hour, the fed tightens its timetable. policymakers predict two rate hikes by 2023 as they inched towards tapering.

and antibody cocktail made by regeneron is showing promise.a study by the university of oxford research team, the therapy reduced the risk of death among hospitalized covid patients by 20%. patients who got it also spent four days less in-hospital on average. regeneron says the benefit is only for people whose bodies don't naturally produce antibodies. finally, google has won a deal to provide french luxury company lvmh with artificial intelligence solutions. the aim is to personalize experiences for customers and faster long-term growth. google will also work with their individual brand to help them recommend products to targeted clients. that does it for this edition of "bloomberg technology." make sure to tune in tomorrow, my colleague will be speaking with bank of america ceo brian moynihan. you don't want to miss that. and, of course, catch "studio 1.0" tonight. this is bloomberg. ♪ >> the following is a paid program. the opinions and views expressed do not reflect those of bloomberg lp, its affiliates, or its employees. ♪ >> the followin

and tell you in regeneron reported the first successful -- intellia and regeneron reported the firstcessful trials. dave wilson is here to explain -- what is that? dave: it is crisper. it is the ability to cut-and-paste dna sequences. two of its developers when the nobel prize in chemistry last year for their work. now you have this company coming out with early-stage study results on a treatment for a liver disease that involves a buildup of protein. it is tied into genetics. we are talking about first stage study. by all accounts, it was very positive. he had a press release out of intellia talking about disease causing proteins. 87%, that is how much this year and that causes this issue was reduced. we are talking about half a dozen patients, so it is early days. but no serious adverse effects from this treatment. it is a matter of taking the technology out of the land -- lab and bringing it to the biotechnology industry. it is the first step and arguably a validation for the technology and not just this particular treatment. alix: not going to affect the rest of the sector? dave:

this on news from the company and its partner regeneron, they've announced positive results in a phase, still phase 1 but a study of crispr based gene editing, a treatment for a genetic nerve disorder regeneron not quite as much. it's phase one, but it's a new -- it's the first therapeutic use for gene editing for crispr, and certainly vie ed as a potentially positive development. >> look, this is great news. this isn't technology. when we first realized that moderna had an rna technology that was incredible. i think it's phase one and they're talking about it, shows there's something very early these are cathie wood stock. this is her. crispr, it b's obvious this is something that's going to work there is no doubt that regeneron's involved, but they don't want to take any credit for what's going on here carl, this could be the beginning of a whole -- this is a very rare disease, but you know, gene editing is the secret for the next generation. >> have you read isaacson's book code breaker >> no, no, it's good isn't it? >> all about the personalities, as he does delving into the lives

. >> reporter: doctors at stanford began treating her with regeneron, the same antibody drug given togranted an emergency use authorization as a treatment by the fda. research continued into the effectiveness for patients who might still be vulnerable, with vaccinations available. >> there are people whose immune system is a great and maybe they're not responding as well to the vaccine. then there are people who have done all the right things, but maybe they're older or have other underlying conditions. >> reporter: as a co-infectious disease expert at stanford which was a trial site for regeneron. the company recently announced the antibody cocktail proved more than 80% effective at reducing the risk of symptomatic covid in phase three trials. they arrest the fda its use as a preventative treatment from vaccinated people, and those with compromised immune systems might respond to vaccines. >> we talked about vaccines and therapeutics. they go hand in hand. >> reporter: and for patients, it's also peace of mind. >> i think we are so blessed we had that treatment. >> doctors at stanfor

. >>> and an antibody treatment plant from regeneron shows significantly cut covid patients, with 10long with the usual care for the virus cut the risk for dying by one-fifth among hospitaled patients who haven't produced the antibody due to the virus. brian, they started introducing that drug for people to get it at early stages before they get hospitalized so it's a very interesting time. >> and yeah, very good news, by the way, hospitalizations and fatalities down 90% from their january high so, some really, really terrific data coming out on this as well. and other health bertha coombs, thank you very much in fact, folks, there are many days fewer than 10,000 new cases. and that's with testing being pretty much cheap or even free and extremely prevalent. very good for the u.s. the fight on covid >>> coming up, a potentially holy grail when it comes to vaccines, vaccines that have nothing to do with covid and a potentially $10 billion marketplace, and maybe the next global health care fight and other key headlines, oracle's fourth quarter earnings, cloud service demands and shares

they say let me buy this i hon fesestly would prefer to you in vertex that got regeneron quinton?ng my call. >> my pleasure, what is going on. >> caller: three years ago you hit a grand slam with and. >> thank you. >> caller: the stock is 20% off the highs and been consolidating for about a year we've also seen a record increase in shares to about 85 million for the past three months i understand the merger abtroj but amd announced a $4 million buy back stock and said they will finish the approval process july 5th. >> right well, look, let's look at it like this. may of last year it was at 52 and now 80 lisa sue is doing an amazing job. here is what i think happens, ultimately when the deal closes, that stock sores. urging you to buy it here and now. can i go to zack in texas, zack? >> caller: jimmy, a big boo-yah. what's up, jimmy >> i don't know. a lot of things are up looking good what's going on? how about a stock? >> caller: life is good, money is good. at the end of the day it's about the money. jimmy, i have 140 shares on at&t. >> and that, ladies and gentlemen is the concl

stocks are popping, regeneron better by 2 1/3%, and the first-ever human study evaluating gene editingthe emerging technology to edit or snip out dna in babies to help avoid a serious illness later on in life. enter 23 and me. one of the leading consumer genetic testing kit companies on the market, and the only one that provides fda approved genetic health risk reports directly to consumers. joining us now, one of the world 's newest billionaires, 23 and me ceo and co-founder ann wojiski. ann, this is incredible stuff and if crispr technology can hopefully enable at some point on a grand scale editing out the genes that predispose people to diseases like alzheimers and diabetes, as i see it 23 and me is sort of the first step in flagging people that they are at risk of these diseases in the first place. how do you view the crispr breakthroughs? >> two things first and foremost look at part of a mission of 23 and me is just understanding the genome. like you can't edit unless you know what you want to edit, so first and foremost like how are we actually going to understand the whole hum

showing signs of life, fda approval, presented asko and biotech starting to act better it could be regeneron's time to make up the lost ground. jack: i like your loyalty, thank you for the great ideas, to read more check out this edition of barron's.com don't forget to follow us on twitter at no, ♪ ♪ from the fox studio in your "maria bartiromo wall street". maria: happy we can walk up to the program that analyzes the week that was in position you for the week ahead. get ready for $100-barrel oil president of hedge fund capital says crude will hit by the end of the year he is warning of a crisis in the next three years what will this mean for the economy and the price you are going to pay at the pump. we have job openings across the country the restaurant industry hit with a one-two punch struggling to full gaps in the work force while food prices skyrocket. i'll be speaking with celebrity chef tom coming up. but first let's take a look back at some of the top. maria: what you want to say to kamala harris what should she be thinking about. >> the root cause of the southern border is water mull

showing signs of life, fda approval, presented asko and biotech starting to act better it could be regeneron's. jack: i like your loyalty, thank you for the great ideas, to read more check out this edition of barron's.com don't forget to barron's.com don't forget to follow us on twitter at ... male announcer: coming up next on "leading the way." dr. michael youssef: your response to god's graciousness with you is of vital importance. jesus tells us that he watches when he gives us small blessings, how faithful you are with that little that he's given you. what you and i need to do is to express grace towards somebody else, to see your blessings as something to be used to bless god, not just for you. announcer: coming up next. ♪♪♪

showing signs of life, fda approval, presented asko and biotech starting to act better it could be regeneron'sck out this edition of barron's.com don't forget to follow us on twitter at ♪ ♪ ♪. larry: hello everyone welcome to "kudlow" i am larry kudlow. a few weeks ago during israel hamas is bull up bombing battles we talked about how the democratic party used to be israel's greatest offenders has turned against israel, even formally as supporters like chuck schumer were basically silent in the face of israeli criticism by the like so far left terrorist sympathizer

showing signs of life, fda approval, presented asko and biotech starting to act better it could be regeneron'snd. jack: i like your loyalty, thank you for the great ideas, to read more check out this edition of barron's.com don't forget to follow us on twitter at >> it's every parent's worst nightmare. your child is born with a deformity -- a face no one wants to see. in poor countries, over 200,000 children a year are condemned to a life of pain and rejection, hoping for the miracle that will change their lives forever.

showing signs of life, fda approval, presented asko and biotech starting to act better it could be regeneron'snk you for the great ideas, to read more check out this edition of barron's.com don't forget to follow us on twitter at no, ♪ ♪ from the fox studio in your "maria bartiromo wall street". maria: happy we can walk up to the program that analyzes the week that was in position you for the week ahead. get ready for $100-barrel oil president of hedge fund capital says crude will hit by the end of the year he is warning of a crisis in the next three years what will this mean for the economy and the price you are going to pay at the pump. we have job openings across

that is monoclonal antibodies, two of which, the regeneron combination and the eli lilly combination, have been approved. i highlighted in blue an additional antibody made by gsk and vir. if you go to the next slide, six days ago, some very interesting and exciting data has been published. that is a randomized placebo-controlled phase three trial of non-hospitalized patients with mild to moderate covid-19 who are at high risk for the progression of their disease, close to 600 people, a single 500 milligram dose of the monoclonal antibody by gsk and vir reduced the risk of hospitalization or death by 85% compared with the placebo. it is well tolerated and there are no safety signals identified. in the test tube, the antibody retains activity against multiple variants. what we really have now are three options within the arena of monoclonal antibodies, something that is important for physicians to know that there is an important option for treating people early to prevent them from going to the hospital. this has been granted an eua so it is available for use and we encourage physicians

a new study finds regeneron's antibody cocktail can save lives in hospitalized covid patients. more about this and also i am told regeneron may advertise on tv its product. is that accurate? >> it is true the region are on results demonstrate a 20% reduction in the death rate of covid 19 in people in the hospital who qualified, who didn't show antibody response but were sick in the hospital and some people are late to develop the antibody response. we know when donald trump was in the hospital his records were released. he didn't have an immediate antibody response, some people developed that down the road. those are great candidates for antibody therapy. there was a reduction of hosteling from 17 days to 13 days and people need to be aware if they go to the hospital or not in the hospital, that is something you want to sweet seek out, you want to ask about it. stuart: maybe -- don't know about the advertising. you brought us a lot of good news and we are grateful. we appreciate it. still on the vaccine, new york celebrating of vaccine milestone. tuesday night new york city lig

marty: drug nicole is referring to is it an iv based on sort of antibodies like the regeneron therapies with covid-19. it is very expensive and she's correct on the fda approved it against the advice of many experts. ... ... >> maybe this is a phoneline issue. but you mention your criticism of doctor fauci a few minutes ago. i wonder how much credit you give former president trump for the development for the vaccines during his time in office or how much criticism or credit for the vaccine rollout quick. >> . >> i don't pay attention to the politicians are the rhetoric we have structural problems it is a criticism of either president by look at it as a bureaucratic problem but operation warp speed is genius it has prevented many great from coming to market look at vaccines most commonly the liability and the uncertainty and for the development to see the power and strength of ingenuity and science to solve problems also i'm a big fan and a lot of those that work in the united states government but the idea that doctors who are political appointees have to say what their boss says or rea

quote, regeneron's chief executive said mr. he did get better, he promised that this would immediately be made available to all americans. >> we have medicines right now, and i call them a cure, we're taking care of our seniors. you're not vulnerable, but they like to say the vulnerable. but you're the least vulnerable. but for this one thing area you -- you are vulnerable and so i am i. you're going to get this free of charge and we're going to get it to you soon. it's made by a number of companies. we're going to get it out to you and take care of our seniors, all free. >> we're going to get it out to you and take care of you. that was on october 8th. and there were 928 covid deaths on that day alone. and until february 2021, nearly 230,000 americans died. and subsequent studies have shown that yet, indeed, unlike the malaria drug or injecting beach, monoclonal antibody treatments have been effective if administered at the onset of illness like it was with trump. according to the fda patients at high risk for disease pro sect

what astra has done here, regeneron did it, is make some antibodies and give it to you.im in this trial was to prevent infection. you and i live in the same house. you get. i going get the shot to make sure i don't get the infection. that's where the 33% came from. it is something that is useful, especially for people who can't take a vaccine or have a breakthrough infection, for example, but it didn't work out this time, except there was a nugget in there which was quite interesting. i told you about it earlier, no? [laughter] alix: no, tell me now. sam: if you keep going down the table they presented, it wasn't necessarily part of the trial design, but there were enough numbers to look for that showed that if people were negative at the time of receiving the antibody injection, i.e. not infected, about seven days afterward, their protection against infection was at 92% efficacy. that is a good number. if they can repeat that in the next trial, then you have a product you could see to protect you for one to four months. guy: let's talk about the data that was last night

an antibody cocktail made by regeneron pharmaceuticals is showing promise, putting to a study by theversity of oxford researchers. the therapy reduced the risk of death among hospitalized covid patients. those who had the cocktail spent four days fewer in the hospital on average. it is only for people whose bodies do not naturally produce antibodies. the world's second-largest software maker's update was not enough to extend the recent rally. the company lagged far behind amazon, microsoft, and google in sales of cloud infrastructure. that is your latest business flash. guy: thank you very much, indeed. lordstown motors and draftkings have both become the targets of short-sellers. they are also part of a broader trend of spac's fading after being taken public area dave wilson is looking at all of this in his chart of the day. dave: absolutely. it is interesting, i come across what is called a dspac index, companies after they complete the merger with a blank check company, a spac, call it what you will, and then go public, as opposed to those that are still looking for deals or have

now when you talk about ivermectin and regeneron and operation warp speed it, can you look back throughsm now of history and realize the politics of many instances? >> we wanted to bring to light all the way the crisis has been politicized. you saw from day one, hydroxy hydroxychloroquine and that knee-jerk anti-trump is a meat at allll worse. we see it going on right now, and we have house republicans trying to convene the committee. and they would not be holding any hearings on this. national security is not aon diversion at this is what they are paid to do. they need to get together and look at this so that something likeey this does not happen aga. even recently, the nih deleted a earlier viral sequences at the request of chinese scientists. why would they do that? actually if we had those earlier sequences that would actually potentially give some credence to the natural spillover theory. but instead, if the virus didn't leak out of that lab then why would they want them deleted it? that needs to be investigated. >> sean: they talk about vaccineti hesitancy, and then ty talk about

showing signs of life, fda approval, presented asko and biotech starting to act better it could be regeneron's time to make up the lost ground. jack: i like your loyalty, thank you for the great ideas, to read more check out this edition of barron's.com don't forget to follow us on twitter at ♪ ♪ ♪. larry: hello everyone welcome to "kudlow" i am larry kudlow. a few weeks ago during israel hamas is bull up bombing battles we talked about how the democratic party used to be israel's greatest offenders has turned against israel, even formally as supporters like chuck schumer were basically silent in the face of israeli criticism by the like so far left terrorist sympathizers, like ilhan omar in the so-called squad, alexandria causing a test, ayanna pressley, rashida tlaib, cori bush, these folks have pushed the democratic party out of israel's camp, completely out it is the gop that is israel's great defender this political ship was triggered by former president trump who kept his promise to move the american embassy to jerusalem and led the negotiations that led to the abraham accords bike goal

an therapeutics like regeneron. jim jordan. >> the other thing, mark is exactly right. we sent a letter to the chairman that is supposed to review any research grant money. we know it didn't go to his board. i would love to question him and find out how many of these projects, how many of these grant dollars, grant applications actually have been in front of his board. we don't know. there is all because of important questions the american taxpayer and the american people deserve answers to. you aree right. president trump did a good job. unfortunately biden got his back to the world health organization. >> sean: senator cruz and senator kennedy really pressed fauci. mark, i will go to you first. at one point, you know, in thise very unique way, which we love about senator kennedy. he said you can't say for certain that you know what they did with that money. can you? and the answer was no.di it was the same with rand paul. it was the sameth with ted cruz. he doesn't know. but it sounds, when i read these emails, to me, like he knew damn well that that possibility exist

now when you talk about ivermectin, regeneron and operation warp speed and shutdowns, can we look backthe prism out of history and realize the politics in many instances won? >> well, sean come of course, the whole reason i wrote the book "panic attack" i wanted to bring all the ways the crisis politicized. you saw day one from hydroxychloroquine, face mask, children in school with vaccines from everything they destroyed with partisan politics. major anti-trump is made it worse. you see it going on right now, we have house republicans trying to convene to look into the origins now that more data continues to come out. we have speaker pelosi saying she will not be holding out any juries on this because it is a diversion. i will tell you what, sean, national security is not a diversion pier that is what they are paid to do. they need to get together and look at this so something like this does not happen again. even recently, sean, the nih deleted viral sequences at the request of chinese scientist. why would they do that? actually come if we have those earlier sequences, that would actu

. >>> regeneron helps cut death rates. own immune systems refuse to respond to the coronavirus. jon? >> apple still pushing to fulfill its health care provisions the tech giant has stumbled in its early efforts. california employees currently testing them are reportedly concerned over the integrity of their health carry apple intended to build upon the success of the smart watch and health apps integrated into ios devices. it's stumbling but i see it differently. the apple watch still represents 40% of the market, far surpassing its closest competitor, samsung. dominating the health tech category well, the struggle is real meanwhile ceo tim cook speaking now at the virtual viva tech conference in paris. julia it seems like with product development, category development, there are some things you talk about health tech i remember a couple of years ago, apple is going to come out with amazon echo and alexa and innovation is dead at apple. apple is making billions of dollars profitably in this category i mean is it struggling

they had a small study only phase one, but stock shot up 50% on the news regeneron is a partner on this, but they pulled back today crispr, similar experiments and their stocks soared today. these are huge holding of cathie wood's revolution etf. like tesla, she believed in gene-editing early and often when we got that way hot consumer price index number in mid-may and wall street decided the fed would have to destroy the economy to save it from inflation, they have tremendous momentum if it's exciting, it goes higher even if it's already got a seemingly insane valuation right now the valuation is irrelevant that's not supposed to happen but it is. these companies have something special. right now wall street likes special. how about nvidia jumping 5% on the possibility that they will be allowed to acquire arm holdings the big money is betting against the steel. remember, they dominate cpus they think it will be blocked. the semiconductor industry hasn't been supportive either. they don't want nvidia to be more powerful. but this weekend we learned that marvel tech, broadcom and media t

regeneron's chief executive said mr.rump's medical staff reached out to the company for permission to use the drug and that it was clear with the drug administration. all we can say is that they asked to be able to use it and we were happy to oblige, they said. when is the president of the united states, of course that obviously gets our attention. not only the trump get this treatment, which rudy giuliani and ben carson also got this treatment. and they had to get a special disposition from the fda to get it from trump. when trump did get better, he chalked it up to this monoclonal antibodies which he touted as a miracle cure and promised he would immediately make it available to all americans. >> we have medicines right now and i call them a cure. we're taking care of our seniors. you're not vulnerable but they like to say the vulnerable but you are the least phone or goal but for this one thing you are vulnerable and so my. but i want you to get the same care that i got. you're gonna get the same medicine. you're gonn

being able to target and essentially use genetic scissors in editing dna intelia partnered with regeneron in applying this and the big landmark we saw in data is this is the first time that the technology has been successfully delivered to the human body systemically. previous applications have required either taking of patient's cells out of the body to do the editing and return them, or injecting directly into the site where you're trying to do the editing like the eye. intelia, in a phase one trial, just reporting six patients worth of data over the weekend, showing this can be done and in fact in trying to edit that gene and not down this protein that causes problems in this very rare disease, this attr, they showed an 87% reduction of that problematic protein in the higher dose this really is a proof of concept for the entire field you're seeing other stocks that do gene etditing, beam therapeutics and verve up 25% there, really showing that people believe this can turn into real medicine you mentioned kathie wood, that etf she put together, focusing on the crisper names that one cat

. >> tim >> yeah, look, regeneron rally 25% with the news also of support for again their whole space. i think you have a case, guy's point on bio gen is a good one and these headlines are fantastic and in this case, the durability of the data is still very shallow and it is a wonderful headline in a complex and important space but i think that is the right call and on the two etfs that the gang has outlined, 145 to 170 is the range on the ibb this break out above 170 is heading that way. >> still ahead, we're after the after hours banks, a few of the big names announcing increases mike mayo said this is a turning point for the group. he'll join us next and later one of our traders went on a crypto buying binge today. they'll tell us why they are picking up serious coin. all of that and more when "fast money" returns >>> welcome back to "fast money. big banks on the move in the after hours. morgan stanley announcing it is doubling the dividend. the next guest said this is a maimer turning point for the sector let's bring in mike mayo from wells fargo. why is this a turning point? >> w

. >> sure a diversified group as well regeneron a leader in molecular medicine cheech at 16 times earnings. they proved that they're the leader when they found -- they are monoclonal antibody is the only one working against covid in record time i really like this stock a lot of shots on goal the next name i'll give you is a growth stock as well stitch fix i really like the business model. they're 6.5 billion-dollar market weight cap company, a lot of data on the customers they know when customers buy products from them and keep them they know who is keeping what and can sell other products to them using the information and data i think this is the future of a owe apparel retail i like the name. they have to execute but i think they are well positioned and then we like energy as well. even though it's had a great run. we think there is more room to go, the companies are being incredibly disciplined with the capex. one of the leaders is eog. we like it here. >> you also own and added to fiver. explain to me what fiver is and why you like it what do they do. >> fiver is a free lanes market we

disease there is an abnormal gene and abnormal gene product it's blocking intellia is working with regeneronr gene editing stocks on the rise the ark genomic revolution etf. this is up like crisper, reagain ner ron and editas. >> a year ago they said it would be a few years before you could use that >> that 52% gain in intellia >> i don't know what's next. you can only imagine how many candidates there are. >> 47,000. >> just overall genes? >> abnormal. >> crisper could fix. >>> perella weinberg with a spac talk to ceo peter weinberg then congressman josh gottheimer joins us to talk taxes and the future of s.a.l.t. rieelf. stay tuned you're watching "squawk box" on cnbc it's another day. and anything could happen. it could be the day you welcome 1,200 guests and all their devices. or it could be the day there's a cyberthreat. get ready for it all with an advanced network and managed services from comcast business. and get cybersecurity solutions that let you see everything on your network. plus an expert team looking ahead 24/7 to help prevent threats. every day in business is a big day. we'

. >> and in talia and regeneron. >> she understand gene editing and getting in flows once in flows, it begins, david. it begins. we're the early -- >> bottom percentile. >> at the early part of her move. >> okay. >> by the way, i'm when i see pieces like emerson breakup. yeah, i know doordash, wells fargo. i know you're going to new geographies and new verticals in europe i have nota doordash order at my restaurant in weeks. had none this weekend. why? because the pandemic in new york is not over. what you don't want to do is order at home, watch a video game and go to bed you want to go out. >> yes. >> spend a lot of money in liquor it's now 60/40 is the break down. >> liquor? >> 60/40 which way? food/liquor or liquor/food. >> liquor. >> okay. >> millennial, it's like you get them they say can i pay 10? this is strange. gen x people, i'll pay 50. gen z, not old enough. i don't have to worry. >> i can't keep my gen's straight. >> talk more what people are spending money on including a big order on united and from "squawk" earlier today the banks raising dividends, guidance on buybacks

david: but what about folks who had covid, maybe even had the antibody treatment as i did, the regeneron it may be that this needs to be nuanced a little more, so that individuals who have immunity to covid and aren't going to be carrying the virus, and they can prove that, you may have to be able to prove that through antibody tests or the like, then they maybe individuals that ought not be required to have a vaccine. david: dr. price good to see you thank you for coming in appreciate it. well, morgan stanley ceo james g orman saying in a virtual conference today he's going to be "very disappointed" if workers don't find their way back to the office after labor day. now gorman vowing people thinking they can be paid new york rates and spend most of their team elsewhere doesn't work. we have more cavuto, which does work, right after this. >> ♪ ♪ ♪ (upbeat music) ♪ ♪ ♪ ♪ ♪ ♪ ♪ ♪ 4. . with comcast business you get the network that can deliver gig speeds to the most businesses and advanced cybersecurity to protect every device on it— all backed by a dedicated team, 24/7. every day in busine

more good news there's the regeneron news today. >> i wish we could hold up the front page of the newnia and new york are now open for business and there were fireworks on last night. i said what? i went to my wife and said what are the fire works for she said we hit 70%. there are parts of the country that wouldn't know what 70% is, and other parts it's herd immunity and we can go anywhere we want and go around the world and go to italy and europe look, he's right >> well -- >> on that note, speaking of being able to go to europe, the eu has added the u.s. to the safe travel list >> it's incredibly important if you're an airline, if you're delta, raise numbers delta i'm not kidding. raise numbers delta. raise numbers united right now. raise numbers. >> people who are raising numbers on things like the cruise lines, the big three got an upgrade, carnival and rcl upgraded at wolf today >> right it was because the people want to cruise badly. >> but we had someone on yesterday in the 10:00 hour who suggested the good news is in the stocks it's not like there's a one-sided view here. thi

substantially reduce the death rate in this country and countries around the world is a pointed out regeneronsibly will never go to your lungs. maria: how worried are you about variants, mike? i mean look, we see this morning, south america has become this new ep center a small population in the world a huge amount quarter of people are dying as a result of covid, throughout the countries of south america partly because of new variants what do you say about these variants, mike. >> at the moment there is a lot of hope that the rna vaccines particularly from pfizer and from moderna and other vaccines on jnj, et cetera, will also deal with these different changes that are occurring mutations virus some antivirals antibodies antibodies will also lessen to burden my feeling what we've seen science wins in reality american science has won this enormous investment our country made over decades was paid off, i think one of the challenges we've is continuing increased manufacturing capability and distributing these throughout the world. that is -- by next year or even later this year, we should be ab

partnership with regeneron. a phase one study of a gene editing treatment but it was positive.market day, i showed you some nice winners. stuart: gene editing is becoming so sophisticated. lauren: i know. stuart: really contributing to medicine. lauren: that is the future. stuart: extraordinary. crisper, the one originally read dna, isn't it? i think the original. dow 30, a sense of the market. about 2/3 down, 1/3 up roughly speaking. dow winners at the top of that list is, there you go, intel up. apple, sales force, microsoft, amgen big names at tom of the dow winners list. s&p 500 winners list, etsy, i call them a chat key exchange that is not being nice to them, up 5%. nasdaq winners headed by nvidia. there you go again. about to do a four-for-one stock split. that always helps the company, the stock i should say. it is up another 4%. >>> there is this. making olympic at olympic trials, new jersey native, sydney mcglocklin shattering the world of 400-meter hurdles. what a development. we'll get into this. >> the father fighting back against critical race theory. here is some